Loading stock data…
AIM ImmunoTech Inc. (AIM)
$0.23+0.00 (+0.92%)
After Hours$0.23+0.00 (+0.17%)· Last close Sep 8
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AIM ImmunoTech Inc. in the Healthcare sector is trading at $0.23 with a market capitalization of $11M. Wall Street consensus targets $4.25 (2 analysts), implying a +1750.2% move over the next 12 months. The stock is currently near its 52-week low of $0.19, remaining 67.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +1750.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | $16,000↓ | $25,000↓ | $26,000↑ | $21,000↓ | $22,000 |
| Gross Profit | $6,000↓ | $15,000↑ | -$42,000↓ | -$19,000↓ | $18,000 |
| Operating Income | -$3.62M↓ | -$2.65M↓ | -$2.45M↑ | -$2.95M↓ | -$2.23M |
| Net Income | -$3.71M↓ | -$2.79M↑ | -$3.28M↑ | -$4.17M↓ | -$3.02M |
Peer Comparison
JNJUNHPFE
Fundamentals
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampli...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-624.75%
Volume
Today's trading volume
5.82M
Recent News
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical
AIM, HAS, FOX, COR and ISRG make the list of stocks with rising P/E ratios, a screen highlighting companies investors may view as having stronger earnings potential.
Bet on 5 Top-Ranked Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns
Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.
AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead
AIM ImmunoTech CEO Thomas K. Equels stated that the company is on track to complete the dosing of Ampligen.
Transcript: Aimia Q1 2026 Earnings Conference Call
On Wednesday, Aimia (TSX:AIM) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://app.webinar.net/EPYVWBVW2wk Summary AIM ImmunoTech Inc announced the divestiture of its specialty chemicals business, Bazzetto, and received regulatory approvals for the t